Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib, Azacitidine, and Venetoclax vs Standard of Care in Fit, Newly Diagnosed, FLT3-ITD Mutated AML (FIT-AML)
NCT07425808Phase 3Not yet recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2026
- Primary completion
- Oct 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of gilteritinib, venetoclax, azacitidine in acute myeloid leukemia (AML), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
gilteritinibvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07425808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07425808.